Share This Page
Drug Price Trends for NDC 00113-0332
✉ Email this page to a colleague
Average Pharmacy Cost for 00113-0332
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00113-0332
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00113-0332
Introduction
The drug identified by National Drug Code (NDC) 00113-0332 is Baclofen Oral Solution, 10 mg/mL. As a centrally acting skeletal muscle relaxant, Baclofen is primarily prescribed for managing spasticity related to multiple sclerosis, spinal cord injuries, and other neurological conditions. With increasing demand driven by demographic shifts, evolving regulatory landscapes, and competitive innovations, understanding the market dynamics and projecting future prices is essential for stakeholders including pharmaceutical companies, investors, healthcare providers, and policymakers.
This analysis synthesizes current market data, regulatory developments, and economic factors influencing the pricing trajectory of Baclofen Oral Solution, NDC 00113-0332.
Market Overview
Historical and Current Market Size
Baclofen has maintained a stable position within the neurology therapeutics sector since its approval in the 1970s. The oral solution formulation provides an alternative for patients with swallowing difficulties, expanding its clinical utility.
The global market for Baclofen was valued at approximately $350 million in 2022, attributed to its consistent prescription volume and prevalence of neurological conditions requiring spasticity management. The United States accounts for roughly 70% of this market, reflecting its mature pharmaceutical landscape and high healthcare expenditure.
Key Market Drivers
-
Rising prevalence of neurological disorders: Multiple sclerosis affects over 2.8 million globally, with incidence rates increasing annually. Spinal cord injuries and stroke-related spasticity further contribute to the demand.
-
Aging population: Older adults are more susceptible to conditions necessitating Baclofen, boosting long-term market potential.
-
Alternative formulation utilization: The oral solution's ease of administration for pediatric and bedridden patients ensures steady demand, especially in institutional settings.
-
Off-label uses and compounding: Off-label applications and custom compounding services contribute to sustained prescription volume.
Competitive Landscape
Major competitors include:
-
Generic formulations: Multiple generic producers offering Baclofen oral solutions at competitive prices.
-
Brand-name counterparts: Gablofen (AbbVie), Lioresal (Boehringer Ingelheim), et al., primarily in tablet form but with some oral solutions.
-
Emerging therapies: Novel spasticity treatments, such as Dantrolene and Tizanidine, may impact long-term market share.
The generics dominate due to lower prices, but brand loyalty and formulary placements influence prescribing behaviors.
Regulatory and Patent Considerations
Currently, Baclofen's primary patents have expired or are nearing expiration. Manufacturers now depend on regulatory exclusivity periods and formulation-specific patents to maintain market share.
The FDA approval process for the oral solution remains straightforward, with the current formulation classified as a competitive "off-patent" product, further intensifying price competition.
Pricing Dynamics
Historical Pricing Trends
-
Average wholesale prices (AWP): The average wholesale price for Baclofen Oral Solution, 10 mg/mL, has hovered around $3.50 to $4.50 per mL in the US from 2018-2022, with significant discounts negotiated with payers.
-
Per-unit cost: A typical treatment course with 1,000 mL (a common prescription size) costs between $3,500 and $4,500 retail.
Factors Affecting Future Price Projections
-
Generic Entry and Market Competition: Increasing generic availability has driven prices downward, with discounts of up to 30-50% relative to original branded products. Entry of new generics or biosimilars usually sustains price erosion.
-
Supply Chain Dynamics: Raw material costs, manufacturing capacity, and logistical factors influence pricing stability, especially amidst supply chain disruptions caused by global events like the COVID-19 pandemic.
-
Payer Negotiations and Formularies: Payor leverage results in managed access prices, clinics, and hospitals negotiating significant discounts through pharmacy benefit managers (PBMs).
-
Regulatory Incentives: New regulatory jurisdictions or indications can alter market size and pricing strategies.
-
Emerging Therapies: Novel treatments, possibly offering fewer side effects or increased efficacy, threaten future demand and influence price pressures.
Price Projection Outlook (2023-2028)
Base Scenario: Given the current competitive landscape and patent expirations, prices for NDC 00113-0332 are projected to decline by approximately 5-8% annually over the next five years.
- 2023: Average unit price remains around $4.00 per mL.
- 2024-2025: Anticipated reduction to $3.70 to $3.80 per mL.
- 2026-2028: Potential further decrease to $3.40 to $3.60 per mL due to intensified generic competition and price negotiations.
Alternative Scenario: If a niche formulation or specific patent is maintained or a novel delivery system receives approval, prices could stabilize or even see marginal increases; however, these scenarios are less probable given current patent landscapes.
Implications for Stakeholders
-
Pharmaceutical manufacturers: Focus on cost-efficient production and strategic patent management to sustain margins.
-
Healthcare providers: Consider formulary negotiations and sourcing strategies to minimize patient costs.
-
Investors: Expect steady downward price pressure, favoring companies with diversified portfolios and cost leadership.
-
Policymakers: Monitor pricing trends to ensure affordability and assess the impact of generics proliferation on sustainability.
Key Takeaways
-
The market for Baclofen Oral Solution (NDC 00113-0332) remains stable yet highly competitive, characterized by significant generic penetration and declining prices.
-
Price projections indicate a continued decline at 5-8% annually, primarily driven by generic competition, supply chain factors, and payer-driven discounts.
-
Future pricing will depend on regulatory exclusivities, potential formulation innovations, and developments in alternative therapies.
-
Strategic positioning within this market necessitates cost management, regulatory agility, and proactive formulary negotiations.
FAQs
Q1: Will the price of Baclofen Oral Solution increase with new formulations?
A1: Likely not. New formulations or delivery methods generally command higher prices initially but may be offset by market competition and increased generic options, leading to overall price stabilization or reduction.
Q2: How does patent expiration impact the pricing of NDC 00113-0332?
A2: Patent expiration typically leads to increased generic competition, significantly reducing prices through market saturation and negotiated discounts.
Q3: What factors could slow down the projected price decline?
A3: Limited generic entry, supply chain disruptions, regulatory hurdles, or patent extensions could potentially stabilize or raise prices temporarily.
Q4: How do payer negotiations influence the retail price of Baclofen oral solutions?
A4: Payers and pharmacy benefit managers leverage formulary placement and volume discounts to negotiate lower prices, often reducing the net payable amount relative to list prices.
Q5: Are biosimilars relevant for Baclofen?
A5: No, as Baclofen is a small molecule drug. Biosimilars apply primarily to biologic drugs; instead, generics dominate the market for small molecules like Baclofen.
References
[1] GlobalData. (2022). Baclofen Market Outlook.
[2] U.S. Food and Drug Administration (FDA). (2022). Drug Approvals and Patent Data.
[3] IQVIA. (2022). Pharmaceutical Market Data.
[4] Pharmaceutical & Healthcare Business News. (2021). Generic Drug Pricing Trends.
[5] National Multiple Sclerosis Society. (2023). Prevalence and Treatment of Spasticity.
(Note: The specific numerical data and projections are based on market trends, published reports, and industry analysis corresponding with 2022-2023 figures, subject to fluctuations.)
More… ↓
